Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Cancer Center, Korea |
---|---|
Information provided by: | National Cancer Center, Korea |
ClinicalTrials.gov Identifier: | NCT00452634 |
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there are emerging interests in their use as anticancer agents based on preclinical evidence of their antiproliferative, proapoptotic, anti-invasive, and radiosensitizing properties. Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase by the statins interferes with the rate-limiting step of the mevalonate pathway, leading to reduced levels of mevalonate and its downstream products, many of which play important roles in critical cellular functions such as membrane integrity, cell signaling, protein synthesis, and cell cycle progression. Perturbations of these processes in neoplastic cells by the statins may therefore result in control of tumor initiation, growth, and metastasis. The statins have demonstrated growth inhibitory activity in cancer cell lines and preclinical tumor models in animals.
Simvastatin, a member of the statin family, profoundly impaired basal and growth factor-stimulated SCLC cell growth in vitro and induced apoptosis. SCLC cells treated with simvastatin were sensitized to the effects of the chemotherapeutic agent etoposide. Moreover, SCLC tumour growth in vivo was inhibited by simvastatin. Therefore, the investigators will conduct this phase II trial to evaluate the efficacy & toxicity of irinotecan/cisplatin plus simvastatin in patients with chemo-naïve ED-SCLC.
Condition | Intervention | Phase |
---|---|---|
Small Cell Lung Cancer |
Drug: Irinotecan Drug: Cisplatin Drug: Simvastatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Irinotecan/Cisplatin Plus Simvastatin in Chemo-Naive Patients With Extensive Disease-Small Cell Lung Cancer |
Estimated Enrollment: | 61 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Irinotecan
Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
Drug: Cisplatin
Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
Drug: Simvastatin
simvastatin 40mg/QD, PO, daily, every 3 weeks
|
Cisplatin-30 mg/m2 on day 1 and 8 repeat q 3 weeks Irinotecan-65 mg/m2 on day1 and 8 repeat q 3 weeks Simvastatin 40 mg per day orally from D1 of cycle 1
Treatment will be continued until disease progression, unacceptable toxicity, or patients' refusal.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
At least one unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST.
2000).
Exclusion Criteria:
Contact: Ji-Youn Han, M.D.,Ph.D. | +82-31-920-1154 | jymama@ncc.re.kr |
Korea, Republic of, Gyenggi | |
National Cancer Center, Korea | Recruiting |
Goyang-si, Gyenggi, Korea, Republic of, 411-769 | |
Contact: Ji-Youn Han, M.D.,Ph.D. +82-31-920-1154 | |
Principal Investigator: Ji-Youn Han, M.D. | |
Sub-Investigator: Jin Soo Lee, M.D. | |
Sub-Investigator: Heung Tae Kim, M.D. | |
Sub-Investigator: Kun Young Lim, M.D. | |
Sub-Investigator: Tak Yun, M.D. |
Principal Investigator: | Ji-Youn Han, M.D.,Ph.D. | National Cancer Center, Korea |
Responsible Party: | National Cancer Center, Korea ( Ji-Youn Han ) |
Study ID Numbers: | NCCCTS-06-176 |
Study First Received: | March 26, 2007 |
Last Updated: | December 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00452634 History of Changes |
Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
Irinotecan cisplatin Simvastatin Extensive disease SCLC |
Antimetabolites Disulfiram Thoracic Neoplasms Carcinoma, Neuroendocrine Simvastatin Antilipemic Agents Irinotecan Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Carcinoma Neuroendocrine Tumors Carcinoma, Small Cell |
Neuroectodermal Tumors Radiation-Sensitizing Agents Cisplatin Respiratory Tract Diseases Lung Neoplasms Lung Diseases Neoplasms, Germ Cell and Embryonal Neuroepithelioma Adenocarcinoma Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |
Antimetabolites Thoracic Neoplasms Molecular Mechanisms of Pharmacological Action Carcinoma, Neuroendocrine Antineoplastic Agents Neoplasms, Nerve Tissue Irinotecan Physiological Effects of Drugs Neoplasms by Site Respiratory Tract Diseases Cisplatin Lung Neoplasms Neoplasms, Germ Cell and Embryonal Therapeutic Uses Respiratory Tract Neoplasms |
Neoplasms by Histologic Type Simvastatin Antilipemic Agents Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Neuroendocrine Tumors Carcinoma Carcinoma, Small Cell Neuroectodermal Tumors Neoplasms Radiation-Sensitizing Agents Lung Diseases Adenocarcinoma |